Leg-worn nerve stimulation device for bowel problems after spinal cord injury
Tests a leg-worn stimulation device for constipation in adults with spinal cord injury.
Key facts
- Who runs it
- University of Michigan
- Where
- Ann Arbor, United StatesSee the site
- Trial code
- Registry title
- Efficacy of a Wearable Noninvasive Neuromodulation Device
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- Jul 2026
- Expected to end
- Nov 2029
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- TNM at a sham-point (AccelBand) - randomized arm
- TNM at a leg point (AccelBand)- randomized arm
- TNM at a leg point (AccelBand)- open-label
- Record updated
- 6 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a spinal cord injury who have bowel problems caused by the injury, such as slow bowel movement and constipation. It tests a leg-worn device that sends mild electrical pulses through the skin.
- Age
- 18 Years and older
- Sex
- All sexes can join
- Disease stage
- Spinal cord injury, caused by trauma or not, above the twelfth chest vertebra (T12). The injury must be incomplete, graded AIS B, C or D. The injury happened at least 6 months ago. Bowel problems caused by the injury.
- Earlier treatment
- People who had gut surgery cannot join, except simple appendix removal, gallbladder removal or caesarean section. People with implanted devices for electrical stimulation cannot join.
- Biomarker or test result
- At least one of the lower spinal reflexes must still be present: bulbocavernosus, patella or Achilles. Some feeling in the leg must remain.
Main reasons for not taking part
- Diabetes, active inflammatory bowel disease, or a severe mental illness now or in the past
- Taking opioid pain medicines every day, or current substance abuse
- An implanted electrical device, such as a heart pacemaker
- Being pregnant or planning a pregnancy
- Needing a breathing machine, or severe autonomic dysreflexia (sudden dangerous rises in blood pressure)
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Traumatic or non-traumatic spinal cord injury (SCI)
- SCI level above the twelfth thoracic vertebra (T12)
- SCI classified as Sensory Incomplete (AIS B), C, or D
- Post-SCI time ≥ 6 months
- Neurogenic bowel dysfunction (NBD) as a result of SCI
- Willing to sign the informed consent form
Who cannot take part
- Prior gastrointestinal surgeries other than uncomplicated appendectomies, cholecystectomy or cesarean sections
- Taking opioid medications on a regular daily basis
- Significant cognitive impairment, impeding the ability to provide informed consent or complete the questionnaire
- Known diagnosis of diabetes mellitus
- Known current or past severe significant psychiatric disorder
- Implanted medical devices for electrical stimulation (e.g. cardiac pacemaker)
- Active inflammatory bowel disease
- Known current substance abuse
- Currently pregnant or actively planning a pregnancy
- Ventilator dependency
- Severe autonomic dysreflexia
- No preservation of the sacral spinal reflexes: bulbocavernosus, patella, or Achilles
- Complete absence of sensation in the leg (since it is needed for calibrating the TNM intensity)
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Caitlin FisherTaking people
About the trial
What the trial wants to find out
The aim of this study is to investigate the potential of transcutaneous neuromodulation (TNM) to treat slow colonic transit and constipation, termed the Neurogenic bowel dysfunction (NBD), in people with SCI. In this project, the study team will investigate the impact of an active treatment intervention vs. a sham control intervention on NBD symptoms in patients with SCI.
Read full original descriptionShow less
The study hypotheses:
* The proposed TNM treatment at a leg point will reduce NBD symptoms between baseline and post-therapy, when compared to the sham-TNM treatment. * The therapeutic effect of TNM to improve the NBD symptoms is associated with improvement of the autonomic function in SCI patients.
The 2 groups in the trial
- Sham (TNM at a sham-point) -Randomized armSham treatment, for comparison
Participants will have a 2-week phase-in period.followed by a 4-week sham treatment. Sham participants can elect to have 2 weeks of open-label treatment once unblinded after 4 weeks of sham.
Treatment: TNM at a sham-point (AccelBand) - randomized arm and TNM at a leg point (AccelBand)- open-label
- Transcutaneous neuromodulation (TNM) at a leg point-Randomized armTreatment being tested
Participants will have a 2-week phase-in period followed by a 4-week treatment phase.
Treatment: TNM at a leg point (AccelBand)- randomized arm
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Early Feasibility Study of Using the AccelBand, a Leg-worn Transcutaneous Neuromodulation (TNM) Device, for Neurogenic Bowel Dysfunction (NBD) in People With Spinal Cord Injury (SCI)
- Plain-language title
- Leg-worn nerve stimulation device for bowel problems after spinal cord injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 6 July 2026